[Pre-clinical study of combined aranosa, cisplatin and irinotecan in the treatment of experimental lung cancer].
Data are presented on evaluation of use of combinations of aranosa (Ar), irinotecan (I) and cisplatin (C) in treatment of Lewis lung carcinoma. The drugs were administered i.p. simultaneously, in single doses: irinotecan 20-100 mg/kg, single dose, cisplatin 2.5 3.0 mg/kg and aranosa 100-200 mg/kg, three doses. High synergism (IP, PAr, IPAr) and sufficient tolerance were reported. Efficiency of IPAr regimen was significantly higher while hematotoxity prognosis - comparable to those of IP.